Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure

Cardiovascular Drugs and Therapy

Volumn 24, Issue 2, 2010, Pages 131-137

  Chirkov, Yuliy Y ^a   De Sciscio, Michele ^a   Sverdlov, Aaron L ^a   Leslie, Sue ^a   Sage, Peter R ^a   Horowitz, John D ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Chronic heart failure; Glyceryl trinitrate; Hydralazine; Nitric oxide; Platelet aggregation; Superoxide; Vasodilatation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OXYGEN; PLACEBO; SPIRONOLACTONE; WARFARIN; NITRIC OXIDE DONOR; SUPEROXIDE;

AFRICAN AMERICAN; AGED; ARTICLE; AUGMENTATION INDEX; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FEMALE; HEART FAILURE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TONOMETRY; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; DRUG RESISTANCE; HEART RATE; HEMODYNAMICS; MANOMETRY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PULSE RATE; VASODILATATION;

ADENOSINE DIPHOSPHATE; AGED; BLOOD; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HEART FAILURE; HEART RATE; HEMODYNAMICS; HUMANS; HYDRALAZINE; MALE; MANOMETRY; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROGLYCERIN; NITROPRUSSIDE; PLATELET AGGREGATION; PULSE; SUPEROXIDES; VASODILATION;

EID: 77955416594     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-010-6233-0     Document Type: Article

References (30)

1. U Elkayam F Bitar 2005 Effects of nitrates and hydralazine in heart failure: clinical evidence before the African American Heart Failure Trial Am. J. Cardiol. 96 37i 43 10.1016/j.amjcard.2005.07.031 1:CAS:528: DC%2BD2MXhtFSmt7%2FI 16226934 (Pubitemid 41437922)
2. Horowitz JD. Nitrovasodilators. In: Loscalzo J, Vita JA, editors. Nitric oxide and the cardiovascular system. Totowa: Humana; 2000. p. 383-410.
3. YY Chirkov JD Horowitz 2007 Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol. Ther. 116 287 305 10.1016/j.pharmthera.2007.06.012 1:CAS:528:DC%2BD2sXhtFSltLjJ 17765975 (Pubitemid 47451509)
4. AL Taylor S Ziesche C Yancy, et al. 2004 Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N Engl J. Med. 351 2049 57 10.1056/NEJMoa042934 1:CAS:528:DC%2BD2cXpslegsrs%3D 15533851 (Pubitemid 39482498)
5. JM Hare 2004 Nitroso-redox balance in the cardiovascular system. (Editorial) N Engl J. Med. 351 2112 4 10.1056/NEJMe048269 1:CAS:528: DC%2BD2cXpslemtr8%3D 15533853 (Pubitemid 39482505)
6. JA Franciosa 2006 Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure Expert Opin. Pharmacother. 7 2521 31 10.1517/14656566.7.18.2521 1:CAS:528:DC%2BD28Xht1OntLvN 17150006 (Pubitemid 44939326)
7. T Münzel S Kurz S Rajagopalan, et al. 1996 Hydralazine prevents nitrate tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug J. Clin. Invest. 98 1465 70 10.1172/JCI118935 8823313
8. A Daiber M Oelze M Coldewey, et al. 2005 Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure Biochem. Biophys. Res. Commun. 338 1865 74 10.1016/j.bbrc.2005.10.106 1:CAS:528:DC%2BD2MXht1Ggu77F 16289107 (Pubitemid 41643103)
9. E Bassenge O Sommer M Schwemmer R Bünger 2000 Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state Am. J. Physiol. Heart Circ. Physiol. 279 H2431 8 1:CAS:528: DC%2BD3cXotFaktbg%3D 11045981
10. H Vidrio P González-Romo E Alvarez C Alcaide F Orallo 2005 Hydralazine decreases sodium nitroprusside-induced rat aortic ring relaxation and increased cGMP production by rat aortic myocytes Life Sci. 77 3105 16 10.1016/j.lfs.2005.03.035 1:CAS:528:DC%2BD2MXhtVOktrbN 15985267 (Pubitemid 41423746)
11. YY Chirkov M De Sciscio AL Sverdlov S Leslie JD Horowitz 2008 Is there a pharmacological hydralazine/nitrate interaction in chronic heart failure? (abstract) Eur. Heart J. 29 300 [P1956]
12. YY Chirkov AS Holmes LP Chirkova JD Horowitz 1999 Nitrate resistance in platelets from patients with stable angina pectoris Circulation 100 129 34 1:CAS:528:DyaK1MXkvV2qtb0%3D 10402441
13. OT Raitakari JP Seale DS Celermajer 2001 Impaired vascular responses to nitroglycerin in subjects with coronary atherosclerosis Am. J. Cardiol. 87 217 9 10.1016/S0002-9149(00)01321-7 1:CAS:528:DC%2BD3MXisVWjsA%3D%3D 11152844 (Pubitemid 32057237)
14. MT Gladwin 2006 Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome J. Clin. Invest. 116 2330 2 1:CAS:528:DC%2BD28Xps1Sgs7Y%3D 16955136
15. YY Chirkov AS Holmes SR Willoughby S Stewart PR Sage JD Horowitz 2001 Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets J. Am. Coll. Cardiol. 37 1851 7 10.1016/S0735-1097(01) 01238-4 1:CAS:528:DC%2BD3MXltVGhsLg%3D 11401122 (Pubitemid 32499970)
16. RA Anderson GR Ellis YY Chirkov, et al. 2004 Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure Eur. J. Heart Fail. 6 47 54 10.1016/S1388-9842(03)00038-2 1:CAS:528: DC%2BD2cXps1yrsw%3D%3D 15012918 (Pubitemid 38169604)
17. YY Chirkov AS Holmes JD Martelli JD Horowitz 2004 Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction Am. J. Cardiol. 93 1438 40 10.1016/j.amjcard.2004.02.052 1:CAS:528:DC%2BD2cXksVGgsL4%3D 15165936 (Pubitemid 38692483)
18. GR Ellis RA Anderson YY Chirkov, et al. 2001 Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial dysfunction in patients with chronic heart failure J. Cardiovasc. Pharmacol. 37 564 70 10.1097/00005344-200105000-00008 1:CAS:528:DC%2BD3MXjtVOltbo%3D 11336107 (Pubitemid 32377912)
19. IB Wilkinson JR Cockcroft DJ Webb 1998 Pulse wave analysis and arterial stiffness J. Cardiovasc. Pharmacol. 32 S33 7 1:CAS:528:DyaK1MXhvV2lsg%3D%3D 9883745
20. EA Liberts SR Willoughby JA Kennedy JD Horowitz 2007 Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris Eur. J. Pharmacol. 560 49 55 10.1016/j.ejphar.2007.01.001 1:CAS:528:DC%2BD2sXisVWnsL8%3D 17292880
21. Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation. In: Harker LA, Zimmerman TS, editors. Measurements of platelet function. New York: Churchill Livingstone; 1983. p. 64-91.
22. NJ Madsen CE Holmes FA Serrano BE Sobel DJ Schneider 2007 Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents Am. J. Cardiol. 100 722 7 10.1016/j.amjcard.2007.03.091 1:CAS:528:DC%2BD2sXovFektrc%3D 17697836 (Pubitemid 47223152)
23. A Daiber A Mülsch U Hink A Warnholtz M Oelze T Münzel 2005 The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine Am. J. Cardiol. 96 25i 36 10.1016/j.amjcard.2005.07.030 1:CAS:528:DC%2BD2MXhtFSmt7%2FP 16226933 (Pubitemid 41437921)
24. H Gogia A Mehra S Parikh, et al. 1995 Prevention of tolerance to haemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure J. Am. Coll. Cardiol. 26 1575 80 10.1016/0735-1097(95)00368-1 1:CAS:528:DyaK28XlvFCqug%3D%3D 7594088
25. U Elkayam IS Karaalp OR Wani P Tummala MW Akhter 1999 The role of organic nitrates in the treatment of heart failure Prog. Cardiovasc. Dis. 4 255 64 10.1053/pcad.1999.0410255 (Pubitemid 29244373)
26. J Bauersachs A Bouloumié D Fraccarollo K Hu R Busse G Ertl 1998 Hydralazine prevents endothelial dysfunction, but not the increase in superoxide production in nitric oxide-deficient hypertension Eur. J. Pharmacol. 362 77 81 10.1016/S0014-2999(98)00763-8 1:CAS:528:DyaK1cXnvFKktbk%3D 9865534 (Pubitemid 29001000)
27. D Salvemini G de Nucci JM Sneddon JR Vane 1989 Superoxide anions enhance platelet adhesion and aggregation Br. J. Pharmacol. 97 1145 50 1:CAS:528:DyaL1MXltFelsro%3D 2551440
28. SW Tam ML Sabolinski M Worcel M Packer 2007 Cohn JN Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox Clin. Pharmacokinet. 46 885 95 10.2165/00003088-200746100- 00006 1:CAS:528:DC%2BD2sXht1yktr%2FK 17854237 (Pubitemid 47443312)
29. JM Flack 2006 Editorial commentary on: Franciosa JA "Fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure Expert Opin. Pharmacother. 8 275 7 10.1517/14656566.8.3.275
30. GT Ellison JS Kaufman RF Head PA Martin JD Kahn 2008 Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients J. Law Med. Ethics 36 449 57 10.1111/j.1748-720X.2008.290.x 18840235